Click on the link to complete the pre-assessment questions before the session begins: https://mli.link/sohotcellpre

SESSION VIII: T-CELL LYMPHOMA

Session Chairs: Matthew A. Lunning, DO, FACP and Jasmine M. Zain, MD

Genetics of PTCL: From Bench to Bedside | Jaehyuk Choi, MD, PhD | UT Southwestern Medical Center, Dallas, Texas, USA

PTCL: When to and When Not to Consolidate in CR1 | Matthew A. Lunning, DO, FACP | University of Nebraska Medical Center, Omaha, Nebraska, USA

Moving Beyond Romidepsin: New Strategies for Relapsed/Refractory PTCL | Jasmine M. Zain, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Can Immunotherapy Become a Reality for T-Cell Lymphoma | Anne W. Beaven, MD | UNC Hospital, Chapel Hill, North Carolina, USA

When MF Goes Bad – Modern Management of Advanced Disease | Pamela B. Allen, MD, MSc | Emory University, Winship Cancer Institute, Atlanta, Georgia, USA

Oral Abstract | TCL-1020: Combination Durvalumab and Lenalidomide Shows Superior Efficacy vs Single-Agent Durvalumab in Refractory/Advanced Cutaneous T-Cell Lymphoma in a Randomized Phase 2 Trial | Christiane Querfeld, MD, PhD | City of Hope, Duarte, California, USA